Acutaas Chemicals Ltd · NSE:ACUTAAS
Acutaas Chemicals — Ami Organics — Investor Presentation (May 2024)
30 slides from Acutaas Chemicals's investor presentation, May 16, 2024
Slide 1: Cover letter to stock exchanges
Ae Ami Organics Limited CIN. : L24100GJ2007PLC051093 Registered Office :- Plot No. 440/4, 5 & 6, Road No. 82/A, G.I.D.C. Sachin, Surat - 394230, Dist. Surat, Gujarat, India. Date: May 16, 2024 To, BSE Limited National Stock Exchange of India Limited Corporate Relations Department Listing Department
Slide 2: Corporate Presentation May 2024
Corporate Presentation M AY 2 0 2 4
Slide 3: Disclaimer
Disclaimer The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any i
Slide 4: Company Overview
£6 AMI ORGANICS LTD. Company Overview
Slide 5: Ami Organics – At a Glance
Ami Organics – At a Glance Business Segments ➢ One of the leading Research and Development driven manufacturer of Specialty Chemicals ➢ Focused on the development and manufacturing of: • Advanced Pharmaceutical Intermediates Advanced Pharmaceutical Specialty • Specialty Chemicals Intermediates Chemi
Slide 6: The Evolution
The Evolution 2004 2005 2006 Formation of partnership firm in the name of Gujarat Gas Safety Award – developing and Change in constitution from partnership firm to “Ami Organics” implementing effective HSE Management private limited in the name of System “Ami Organics Private Limited” 2016 2015 2011
Slide 7: Business Segments
Business Segments Advanced Pharmaceutical Specialty Chemicals Intermediates ➢ ~500 Products invoiced in last 5 years ➢ Parabens & Paraben formulations ➢ Salicylic Acid ➢ Intermediates across 17+ therapeutic ➢ Niche KSMs for cosmetics, finechem and areas agrochem companies ➢ ~95% Chronic Therapy focu
Slide 8: Advanced Pharmaceutical Intermediates
Advanced Pharmaceutical Intermediates Historical Business Performance (INR mn) 5,678 17+ 150+ CAGR 25% FY24 Therapeutic Customers 5,678 5,180 Revenue Areas in FY24 (INR mn)) 4,270 3,240 2,322 25+ 15 2 FY20 FY21 FY22 FY23 FY24 Countries Process Patents Manufacturing (Customer locations) (1 patent pub
Slide 9: Our Business Model – Advanced Pharmaceutical Intermediates
Our Business Model – Advanced Pharmaceutical Intermediates CDMO Business ➢ Contract Manufacturing for big pharma companies ➢ Exclusive long term supply contracts ~10% Innovator Business ➢ Supplying NCE molecules to the pharma innovator companies ➢ Supplying intermediates to innovator pharma companie
Slide 10: Speciality Chemicals
Speciality Chemicals Historical Business Performance (INR mn) 1,497 3 40+ CAGR 112% FY24 Business Products 1,497 Revenue Segments ➢ Specialty Chemicals for various industries e.g. (INR mn) Cosmetics, Finechem, Agrochem, etc. ➢ Battery Chemicals 932 990 ➢ Semiconductor Chemicals 166 74 340+ 40+ 2 FY2
Slide 11: Strong and Long-term Relations with Diversified Customers across Geographies
Strong and Long-term Relations with Diversified Customers across Geographies Revenue Contribution from Top Customers - FY24 ➢ Well established long-term relations with domestic customers 500+ 57% Customers as well as MNCs across large and fast-growing markets 46% ➢ Diversified customer base 39% ~60
Slide 12: State-of-the-Art Manufacturing Facilities
State-of-the-Art Manufacturing Facilities 76,891 ~1,100 Total Land Area (sq mtrs) Total Installed Capacity (KL) Sachin, Gujarat Ankleshwar, Gujarat Jhagadia, Gujarat Greater Noida, UP Land Area Installed Capacity Land Area Installed Capacity Land Area Installed Capacity Land Area Installed Capacity
Slide 13: R&D Centric Organization…
R&D Centric Organization… R&D Expenditure State-of-the-Art (INR mn) 1 R&D Lab 2 Technology 3 Equipment 65 70 77 141 ADL fully supported by analytical • Modern fume hood system 23,681 sq. ft. instruments like: • Autoclave State of art R&D facility at Sachin R&D expenditure as % • LCMASS • High vacuum
Slide 14: …with Capability in Key Chemistries
…with Capability in Key Chemistries Etherification Acylation Fluorination Nitration Esterification Bromination Diazotization Hydrogenation Alkylation Amination Chlorination & Hydrolysis AMI Organics R&D Centre in Surat 13
Slide 15: ESG Focus – Working towards a Better Tomorrow
ESG Focus – Working towards a Better Tomorrow Environment Social Governance ➢ Zero Liquid Discharge based in-house ➢ Company’s Sachin facility is SA 8000:2014 ➢ 50% of the board constitutes of effluent plant at Sachin facility certified independent directors ➢ 80% of wastewater recycled ➢ The SA8000
Slide 16: Our Founders
Our Founders ➢ Mr. Nareshkumar Patel is founder of the Company ➢ He has been associated with the Company since its inception and has extensive experience in the global generic pharma business ➢ He is responsible for handling the Chemical Engineering and Product Implementation divisions of the Compan
Slide 17: Our Leadership
Our Leadership Board of Directors Virendra Girikrishna Richa Hetal Dr. Anita Mr. Ram Mohan Mishra Maniar Goyal Gandhi Bandyopadhyay Lokhande Whole – time Non – executive, Non – executive, Non – executive Independent Whole – time Director Independent Director Independent Director Independent Director
Slide 18: Consistent Financial Performance
Consistent Financial Performance Revenue from Operations- Growth Trends (INR mn) FY20 FY21 FY22 FY23 FY24 FY20-24 CAGR: 25% 112% 32% 7,175 6,170 5,678 5,180 5,201 4,270 3,240 3,406 2,322 2,396 1,497 932 990 74 166 Advance Intermediates Chemicals Total EBITDA and EBITDA Margin PAT and PAT Margin (%)
Slide 19: What Makes Us Different ?
What Makes Us Different ? Niche Product Portfolio High Entry Diversified Products to Diversified Customer Reputation for Robust Cost with a Strong Market Barriers Support Future Growth Base across Innovative Product Management / Process Share Geographies Launches Supported by Improvements Robust R&D
Slide 20: Strategies to Drive Future Growth
Strategies to Drive Future Growth 19
Slide 21: Our Strategy – Advanced Pharmaceutical Intermediates
Our Strategy – Advanced Pharmaceutical Intermediates Grow the Innovator business with more focus on CDMO opportunities S T R Commercialise products way ahead of time for drugs going off-patent in the coming years A T Continue to develop innovative products for the global market E G Y Ramp up product
Slide 22: Our Strategy – Speciality Chemicals
Our Strategy – Speciality Chemicals Development and entry Continue to work on into newer applications improving operational having strong entry efficiencies to deliver barriers better margins Leverage the technology Grow the Battery and capability of Baba Fine Chemicals segment – Chemicals to expand
Slide 23: Industry Overview
£6 AMI ORGANICS LTD. Industry Overview
Slide 24: Industry Overview (1/2)
Industry Overview (1/2) Global API Market Global Pharmaceutical Intermediates Market (USD bn) (USD bn) 6.5% CAGR 326 6.2% CAGR 51 6.1% CAGR 238 6.0% CAGR 37 177 28 2018 2023 2028E 2018 2023 2028E Global API Market Split by Therapy 15% 19% CAGR CAGR 27% 25% (2018-23) (2023-28E) 35% 33% Oncology 11% 1
Slide 25: Industry Overview (2/2)
Industry Overview (2/2) Global Electrolyte Additives and Electrolyte Solutions Market Global Specialty Chemicals Market 20.2 (USD bn) 11.2 (USD bn) 6.5 1,219 3.4 0.8 1.6 937 2018 2023 2028E 785 Electrolyte Additives Electrolyte Solutions Global Photoresist Chemicals and Semiconductor Chemicals Marke
Slide 26: Appendix
£6 AMI ORGANICS LTD. Appendix
Slide 27: Statement of Profit and Loss
Statement of Profit and Loss Particulars (INR mn) FY21 FY22 FY23 FY24 Revenue from Operations 3,406 5,201 6,167 7,175 Other Income 14 28 43 75 Total Income 3,420 5,229 6,210 7,250 Cost of materials consumed 1,749 2,823 3,459 4,402 Changes in inventories of finished goods, traded goods and work-in-pr
Slide 28: Balance Sheet
Balance Sheet Assets (INR mn) FY21 FY22 FY23 FY24 Equity and Liabilities (INR mn) FY21 FY22 FY23 FY24 Property, plant and equipment 1,422 1,584 1,844 3,229 Shareholder's equity 1,669 5,223 5,939 6,828 Right of use assets 184 194 374 372 Capital work-in-progress 2 30 255 1,254 Borrowings 726 6 6 1,13
Slide 29: Cash Flow Statement
Cash Flow Statement (INR mn) FY21 FY22 FY23 FY24 Cash flow from operating activities Profit before tax 717 914 1,122 819 Operating profit before working capital changes 797 1,059 1,263 1,317 Cash generated from operations 421 141 900 1,495 Income tax paid (142) (228) (245) (243) Net cash (used) / ge
Slide 30: Thank You
£6 AMI ORGANICS LTD. Thank You